Filing Flows › TG Therapeutics (TGTX) › Q3 2026 › vs Q2 2026
TG Therapeutics (TGTX) Q3 2026 vs Q2 2026 (quarter over quarter)
TG Therapeutics's revenue rose $19.6M (+8%) from $240M in Q2 2026 to $260M in Q3 2026. Operating margin 33.0% against 9.0% (+24.0 pts).
TG Therapeutics, Q3 2026: revenue $260M (+61% year over year), operating margin 33.0%, net earnings $55.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 33.0% | 9.0% | +24.0 pts |
| Net margin | 21.3% | 3.2% | +18.1 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $260M | $240M | $19.6M | +8% |
| Operating profit | $85.9M | $21.7M | $64.2M | +296% |
| Costs & expenses | $174M | $219M | −$44.6M | -20% |
| Pre-tax earnings | $73.9M | $10.2M | $63.6M | +622% |
| Other expense, net | $12.0M | $11.4M | $597K | +5% |
| Cost of revenue | $42.1M | $41.2M | $885K | +2% |
| Net earnings | $55.5M | $7.8M | $47.7M | +613% |
| Income tax | $18.4M | $2.5M | $15.9M | +650% |
Questions
How much did TG Therapeutics's revenue grow quarter over quarter in Q3 2026?
TG Therapeutics's revenue rose $19.6M (+8%) from $240M in Q2 2026 to $260M in Q3 2026. Operating margin 33.0% against 9.0% (+24.0 pts).